Search Results

The ExaStim Stimulation System is indicated for the improvement of hand sensation and strength in individuals between 18 and 75 years old who present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury, when used in conjunction with functional task practice.

The ExaStim® Stimulation System is designed to deliver transcutaneous electrical spinal stimulation for therapeutic use in individuals with incomplete spinal cord injury (SCI). The ExaStim Portable Stimulator is a battery-operated medical device composed of specialized electronics and embedded firmware. It emits stimulation according to parameters configured by the ExaStim Programmer by a clinician.

The ExaStim Stimulation System consists of the components described in Table 1.

In addition to the components listed above, the system requires two PALS‡ Neurostimulation Electrodes manufactured by Axelgaard, as shown in Table 2 which are not included with the system.

N/A

Ask a specific question about this device

The Remote Wave Electrode is to be used exclusively for external prosthetic fittings of the upper limbs.

Remote Wave Electrode is an active analogue electrode for detecting any surface electromyographic signals, used for controlling prosthetic devices. It is compact and low-power, ensuring an accurate and fast reading of muscle electrical potentials generated voluntarily by the user. It also provides a real-time output signal proportional to the detected muscle activation.

Through the Remote Wave Electrode it is possible to non-invasively detect the electrical signal produced by the residual muscles on the patient's amputated limb (unilateral or bilateral amputees, starting from a transradial amputation level) and send an electrical signal to the electronic board of the prosthetic hand with a proportional width to the detected contraction.

Remote Wave Electrode is only compatible with the Adam's Hand Family, including Adam's Hand (medium e small), Adam's Hand Plus and Adam's Hook prosthetic hands that, according to the Regulation Number 890.3420, are classified as class I medical devices.

Remote Wave Electrode is available in two different models:

• Mod. AE03-50, with notch filter centred on the 50 Hz frequency;
• Mod. AE03-60, with notch filter centred on the 60 Hz frequency

N/A

Ask a specific question about this device

The Ceribell Instant EEG Headset is intended for use in routine clinical settings where rapid placement of a number of EEG electrodes is desired.

The Ceribell Instant EEG Headset is a single-use, non-sterile, disposable EEG electrode device that includes up to 20 EEG electrodes that are placed on the subject's scalp. The headset is a prescription-use device intended to collect and provide EEG signals to an EEG recording or monitoring device.

The Ceribell Instant EEG Headset includes the following components:

• Elastic fabric headset
• Electrode assemblies, each consisting of the following:
  • Passive silver/silver chloride (Ag/AgCl) electrode
  • Reservoir filled with conductive electrolyte gel
• Mechanism for dispensing gel onto patient scalp
• Scalp-contacting prongs to prepare scalp for electrode contact
• Cable attached to the headset to allow connection to an EEG acquisition/recording device

N/A

Ask a specific question about this device

The SafeOp 3: Neural Informatix System is intended for use in monitoring neurological status by recording transcranial motor evoked potentials (MEP), somatosensory evoked potentials (SSEP), electromyography (EMG), or assessing the neuromuscular junction (NMJ). Neuromonitoring procedures include intracranial, extracranial, intratemporal, extratemporal, neck dissections, upper and lower extremities, spinal degenerative treatments, pedicle screw fixation, intervertebral fusion cages, rhizotomy, orthopedic surgery, open/percutaneous, lumbar, thoracic, and cervical surgical procedures.

SafeOp 3 Accessories: The SafeOp Accessories are utilized in spine surgical procedures to assist in location of the nerves during or after preparation and placement of implants (intervertebral fusion cages and pedicle screw fixation devices) in open and percutaneous minimally invasive approaches.

The SafeOp™ 3: Neural Informatix System (SafeOp 3 System), consists of the SafeOp patient interface with power supply and IV pole mount, the Alpha Informatix Tablet with docking station and power supply and a data transfer USB cable. Associated disposable accessories consists of an electrode harness, surface and/or subdermal needle electrodes, MEP Activator, Cranial Hub, Delta Dilators and Stimulating Probe and Delta Clip contained in various kits.

The subject device is intended for use by trained healthcare professionals, clinical neurophysiologists/technologists and appropriately trained non-clinical personnel. The subject device is intended for use in operating room environments of hospitals and surgical centers. System setup may be performed by both clinical and trained non-clinical personnel.

The provided FDA 510(k) clearance letter and summary for the SafeOp 3: Neural Informatix System (K252842) primarily describe the device's substantial equivalence to a predicate device (K234092) and outline a Predetermined Change Control Plan (PCCP) for future modifications. However, it does not include a detailed study proving the device meets specific acceptance criteria in the context of clinical performance or AI algorithm validation for the initial clearance.

The "Performance Data" section explicitly states: "Determination of substantial equivalence is not based on an assessment of clinical performance data." and refers to nonclinical performance testing (functional, system, software requirements) and usability testing.

Therefore, the following information is extracted and synthesized based on the available document, but a comprehensive study proving acceptance criteria for all aspects of neural informatic performance is not present. The document focuses on the future PCCP for algorithmic changes, which will have performance criteria.

Acceptance Criteria and Reported Device Performance

The core of the documentation for this 510(k) clearance is about demonstrating substantial equivalence to an existing predicate device (SafeOp 3™: Neural Informatix System, K234092). Therefore, the "acceptance criteria" for the cleared device itself are primarily its ability to match the predicate's performance and specifications, which is shown through a direct comparison.

The document does not report specific quantitative performance metrics for the SafeOp 3: Neural Informatix System for its initial clearance, as it relies on substantial equivalence.

However, the Predetermined Change Control Plan (PCCP) outlines future modifications to the SSEP Baseline Classification Algorithm and defines acceptance criteria for these future algorithmic changes. These are the only explicitly stated performance acceptance criteria in the document.

Table 1: Acceptance Criteria and Reported Device Performance (from PCCP for future algorithmic changes)

Study Details (Based on the document, for the initial clearance)

Because the 510(k) is based on substantial equivalence and explicitly states "Determination of substantial equivalence is not based on an assessment of clinical performance data," there is no detailed "study" proving the device meets acceptance criteria in the way a de novo or PMA submission might. The "study" mentioned below refers to the verification and validation activities conducted to demonstrate substantial equivalence and safety/effectiveness for the initial clearance, as described in the "Performance Data" section.

1. Sample size used for the test set and the data provenance:

   • Not explicitly stated for clinical performance data for the initial clearance. The document mentions "nonclinical performance testing" for functional, system, and software requirements, and "usability testing." These typically involve controlled test cases and user interactions rather than a large clinical test set.
   • For the future PCCP modifications of the SSEP algorithm, it mentions "an independent, firewalled dataset" and "additional labeled data" for re-training and testing, but no sample size or provenance is specified within this document.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • Not explicitly stated for the initial clearance. Since the clearance is based on substantial equivalence and does not assess clinical performance data, detailed expert ground truth establishment for a clinical test set is not described.

3. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

   • Not explicitly stated for the initial clearance. Not applicable given the reliance on substantial equivalence and lack of clinical performance data assessment.

4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • No. The document does not describe an MRMC study. The device is a neural informatic system, and while it involves signal processing, it's not positioned as an AI-assisted diagnostic tool that human readers would interpret with assistance in the traditional sense of an MRMC study. The SSEP algorithm mentioned in the PCCP appears to be a standalone classification, not a human-in-the-loop assistance tool subject to such a study.

5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

   • For the initial clearance, the document refers to "nonclinical performance testing" demonstrating the system meets functional, system, and software requirements. This implies standalone testing of device functions.
   • For the future SSEP Baseline Classification Algorithm (PCCP Modification #1 & #4), the acceptance criteria (PPV, Accuracy, F1-score) clearly indicate standalone algorithm performance is intended to be evaluated. However, no such standalone performance data is provided for the initially cleared device.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

   • Not explicitly stated for the initial clearance. For the "nonclinical performance testing" and "usability testing," ground truth would typically be established based on engineering specifications and validated operational procedures.
   • For the future SSEP Baseline Classification Algorithm (PCCP Modification #1 & #4), it refers to "labeled data," which implies a ground truth established by experts or other definitive methods, but the specific type is not detailed in this document.

7. The sample size for the training set:

   • Not explicitly stated for the initial clearance. No AI algorithms are reported as being evaluated for the initial clearance.
   • For the future SSEP Baseline Classification Algorithm (PCCP Modification #1 & #4), it mentions the algorithm "will be re-trained using site-specific data" and "periodically re-trained as additional labeled data become available," but no sample size is specified within this document.

8. How the ground truth for the training set was established:

   • Not explicitly stated for the initial clearance.
   • For the future SSEP Baseline Classification Algorithm (PCCP Modification #1 & #4), it refers to "labeled data," but the method of labeling (establishing ground truth) is not detailed in this document.

Ask a specific question about this device

The Ceribell Instant EEG Headcap is intended for use in routine clinical settings where rapid placement of a number of EEG electrodes is desired. The headcap shall be placed on the head of infants, including newborns and preterm babies.

The Ceribell Instant EEG Headcap is a single-use, non-sterile, disposable EEG electrode device that includes a minimum of 9 EEG electrodes that are placed on the subject's scalp. The Headcap is intended to collect and provide EEG signals to an EEG recording or monitoring device.

The Ceribell Headcap includes the following components:

• An elastic fabric headcap
• An elastic fabric chin strap
• Nine (9) silver/silver chloride (Ag/AgCl) electrodes
• A cable attached to the headcap to allow connection to an EEG acquisition/recording device

N/A

Ask a specific question about this device

Electrotherapy Electrodes are intended for use as the disposable, conductive adhesive interface between the patient's skin and the Electrical Stimulator. Electrotherapy Electrodes are intended to be used with marketed Electrical Stimulators, (i.e. TENS (Transcutaneous Electrical Nerve Stimulation), EMS (Electrical Muscular Stimulation), IF (Interferential) or PGF (Pulsed Galvanic Stimulation)) for transmitting electrical current. The electrodes are for OTC (Over-The-Counter) or Prescription use.

Electrotherapy Electrodes provide a means for establishing electrical contact between the lead connected to a TENS, EMS or NMES stimulation device and the skin, and are multi-layer, flexible structures composed of laminated materials commonly used in the application:

1st layer: Insulation material: Tan fabric
2nd layer: Double sides adhesive tape
3rd layer: Conductive film (Carbon Film)
4th layer: Self-adhesive conductive hydrogel
5th layer: Plastic release film
Connection: Leadwire/Snap button

The electrodes are designed for single-patient & single application use. Because of the adhesive nature of the conductive hydrogel, no securing materials are required to secure the device to the patient's skin.

The provided FDA 510(k) clearance letter and summary for the Electrotherapy Electrodes (K250841) does not describe a study involving AI or human reader performance. Instead, it focuses on demonstrating substantial equivalence to a predicate device through non-clinical performance and biocompatibility testing.

Therefore, many of the requested details about acceptance criteria for AI and human performance studies, expert involvement, adjudication, MRMC studies, standalone AI performance, and ground truth establishment cannot be found in this document.

However, I can extract the acceptance criteria and performance data related to the non-clinical tests that were performed to demonstrate substantial equivalence for this device.

Acceptance Criteria and Device Performance (Non-Clinical)

The device, Electrotherapy Electrodes (K250841), is a Class II cutaneous electrode. The study described focuses on demonstrating its substantial equivalence to a predicate device (ZMI Self-Adhesive Electrodes, K180865) primarily through non-clinical performance and biocompatibility testing. No AI component or human reader study is discussed.

1. Table of Acceptance Criteria and Reported Device Performance (Non-Clinical)

Based on the provided document, the following information is NOT available as the submission does not involve an AI or human reader performance study:

2. Sample sizes used for the test set and the data provenance: Not applicable to this type of non-clinical device testing.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable. Ground truth for these tests is based on objective measurements against engineering and safety standards.
4. Adjudication method for the test set: Not applicable.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, if so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.): For this device, "ground truth" refers to compliance with established industry standards (e.g., IEC, ISO, ASTM) and internal performance specifications.
8. The sample size for the training set: Not applicable (no AI model).
9. How the ground truth for the training set was established: Not applicable (no AI model).

Ask a specific question about this device

The TeleRehab® Aermos Cardiopulmonary Rehabilitation System is intended to acquire and condition the ECG signal from a patient so that it can be transmitted wirelessly from a radiofrequency transmitter to a workstation in a hospital or a clinical setting where the data is displayed and analyzed. This device also measures heart rate and provides visual and audible alarms if the patient's heart rate goes out of a prescribed range. This device is for use with ambulatory adult patients who need monitoring while undergoing cardiovascular and/or pulmonary rehabilitation. The physiological data from monitoring and other patient information (such as patient demographics, exercise protocol and medical information) is stored in a database for tracking and reporting of the patients' progress through rehabilitation.

The TeleRehab® Aermos Cardiopulmonary Rehabilitation System ("Aermos") provides the ECG monitoring functionality required for performing rehabilitation of cardiovascular and/or pulmonary patients. Patients' ECG may be monitored using the Aermos system during exercise under clinical supervision. During monitoring, Aermos provides both visual and audible alarms if the patient's heart rate goes out of a prescribed range. The heart rate alarm indication is one of multiple inputs a clinician may use to modify and adjust rehabilitation activities such as decreasing the patient's level of physical exertion or halting the exercise entirely.

Aermos also provides the ability to plan a patient's rehabilitation program and document the patient's progress through the creation of various types of reports. The report types supported in Aermos include individual treatment plan reports, daily exercise session reports and various patient information reports. Additionally, the Aermos system provides the ability to transfer various report types to the hospital Electronic Medical Records system.

The main components of Aermos are Argus ECG transmitters, the Aermos Workstation and associated networking equipment.

This FDA 510(k) clearance letter pertains to the TeleRehab Aermos Cardiopulmonary Rehabilitation System, which is a device for monitoring ECG signals and heart rate during patient rehabilitation. The provided documentation (the 510(k) Summary) details non-clinical bench testing for performance and safety but explicitly states that clinical testing was not applicable.

Therefore, based on the provided document, the following information regarding acceptance criteria and a study that proves the device meets those criteria, specifically concerning an AI/algorithm-driven component with clinical performance metrics, cannot be fully extracted or is explicitly stated as not performed:

Here's an analysis of the provided information relative to your request:

Acceptance Criteria and Device Performance (Based on Non-Clinical Bench Testing)

Since no clinical study was performed, the "reported device performance" would pertain to the results of non-clinical bench testing against established performance standards. The document does not provide specific quantitative acceptance criteria or reported numerical performance results for the device. Instead, it states that the device's specifications were "verified through internal verification testing" and its usability "evaluated through internal validation testing," and that it complies with various international standards.

Study Details (Based on the provided 510(k) Summary)

1. A table of acceptance criteria and the reported device performance:

   • See the table above. Specific quantitative acceptance criteria beyond "compliance with standard" are not provided in this regulatory summary.

2. Sample size used for the test set and the data provenance:

   • The document explicitly states "Clinical Testing: Not applicable."
   • For the non-clinical bench testing, specific sample sizes (e.g., number of devices tested, number of test cases) are not detailed in this 510(k) summary.
   • Data provenance for non-clinical testing would typically be internal laboratory data generated during device development and verification. There is no mention of geographical origin or retrospective/prospective nature as this was not clinical data.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • Not applicable, as no clinical study with human interpretation/ground truth was performed. The "ground truth" for bench testing would be defined by validated test equipment and reference standards.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

   • Not applicable, as there was no study involving human readers or interpretation requiring adjudication.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, if so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • No MRMC study was done, as clinical testing was "Not applicable." The device is a physiological signal monitor, not an AI-assisted diagnostic tool that interprets images or signals requiring human reader comparison.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

   • The core functionality of the device (ECG acquisition, heart rate measurement, alarms) is algorithmic. The performance of these algorithms would have been assessed during the non-clinical bench testing, which is essentially "standalone algorithm" testing against known inputs and expected outputs. Specific quantitative results (e.g., algorithm accuracy for heart rate) are not provided in this summary beyond "compliance with IEC 60601-2-27" and "ANSI/AAMI EC57: 2012, Testing and Reporting Performance Results of Cardiac Rhythm and ST-Segment Measure Algorithms."

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

   • For non-clinical bench testing, the "ground truth" is typically established by:
     • Reference standards and calibrated test equipment: For electrical performance, signal acquisition accuracy, frequency response, etc.
     • Simulated physiological signals: For testing heart rate calculation and alarm thresholds.
     • Design specifications and established engineering principles: For software functionality and cybersecurity.

8. The sample size for the training set:

   • Not applicable. The device is a monitoring system and not primarily driven by a deep learning or machine learning algorithm that requires a "training set" in the sense of a large dataset for model development. The algorithms for heart rate calculation, etc., are likely traditional signal processing algorithms.

9. How the ground truth for the training set was established:

   • Not applicable, as there was no training set for a machine learning model.

Summary of Device Nature and Regulatory Pathway:

The TeleRehab Aermos Cardiopulmonary Rehabilitation System is a Class II device (Product Codes DRG, DRT) which functions as a physiological signal transmitter and receiver. It monitors ECG and heart rate and provides alarms. Its 510(k) clearance relied on demonstrating substantial equivalence to predicate devices primarily through non-clinical bench testing against recognized industry standards (e.g., IEC 60601 series, ANSI/AAMI, ISO standards) and adherence to FDA guidance documents (e.g., for software, cybersecurity, reprocessing). The explicit statement "Clinical Testing: Not applicable" indicates that the nature of the device and its intended use, combined with the comprehensive non-clinical data, satisfied the FDA's requirements for demonstrating safety and effectiveness without the need for a human-subject clinical study. This is common for devices that are evolutionary improvements on existing technologies with well-understood performance parameters.

Ask a specific question about this device

The REMI Remote EEG Monitoring System is indicated for use in healthcare settings where near real-time and/or remote EEG is warranted and in ambulatory settings where remote EEG is warranted. REMI System uses single patient, disposable, wearable sensors intended to amplify, capture, and wirelessly transmit a single channel of electrical activity of the brain for a duration up to 30 days.

REMI System uses the REMI Mobile software application that runs on qualified commercial off-the-shelf mobile computing platforms. REMI Mobile displays user setup information to trained medical professionals and provides notifications to medical professionals and ambulatory users. REMI Mobile receives and transmits data from connected REMI Sensors to the secure REMI Cloud where it is stored and prepared for review on qualified EEG viewing software.

REMI System does not make any diagnostic conclusion about the subject's condition and is intended as a physiological signal monitor. REMI System is indicated for use with adult and pediatric patients (1+ years).

The REMI System has three major components:

• 1. REMI Sensor A disposable EEG sensor which is placed on the patient's scalp using a conductive REMI Sticker
• 2. REMI Mobile A mobile medical application that is designed to run on a qualified commercial-off-the-shelf mobile computing platform (an Android tablet for use in healthcare settings, and a portable/wearable Android device (phone or smartwatch) for use in ambulatory settings), acquire EEG data transmitted from REMI Sensors and then transmit the EEG data and associated patient information via wireless encrypted transmission to.
• 3. REMI Cloud A HIPAA-compliant secure cloud storage and data processing platform where data is processed into a qualified EEG reviewing software format for neurological review.

The provided document is a 510(k) Pre-market Notification Summary for the REMI Remote EEG Monitoring System (K243185). This document details the device's characteristics, indications for use, and the studies conducted to demonstrate its substantial equivalence to a predicate device (REMI Remote EEG Monitoring System, K230933).

Based on the provided information, here's a description of the acceptance criteria and the study that proves the device meets them:

1. Table of Acceptance Criteria and Reported Device Performance

The document primarily relies on comparisons to its own predicate device (K230933) and general performance testing against recognized standards. Specific quantitative acceptance criteria are not explicitly detailed in a table format within this summary, but the general assertion is that the device met all predetermined acceptance criteria derived from the listed tests.

2. Sample Size Used for the Test Set and Data Provenance

• Clinical Performance Test Set (Pediatric Extension):
  • Sample Size: 13 younger pediatric patients (ages 1 to <6 years)
  • Data Provenance: Retrospective review of existing REMI EEG records gathered from NIH-funded studies conducted by Epitel in support of REMI development efforts. Data collected under IRB oversight and registered under NCT03583957. The document states a single pediatric-focused site was involved.
  • Geographic Origin: Not explicitly stated, but NIH funding implies a U.S. origin.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

• Number of Experts: One
• Qualifications: An "experienced pediatric epileptologist independent of wired EEG and generally separated in time from the actual time of collection by over a year - to ensure appropriate experience, consistency, and minimization of bias."

4. Adjudication Method for the Test Set

• Adjudication Method: None explicitly described beyond a single expert's retrospective review. The expert's review was the ground truth.

5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study

• MRMC Study Done? No. The document describes a retrospective review by a single expert to affirm the clinical value of the EEG records, not a comparative effectiveness study pitting human readers with vs. without AI assistance. The device is a physiological signal monitor, not an AI diagnostic tool in this context.

6. Standalone (Algorithm Only) Performance

• Standalone Performance Done? The "Software Verification Testing" section describes end-to-end testing of the system (acquiring, transmitting, and making data viewable), which is essentially testing the algorithm's ability to process and present the data. It verifies the functionality of the system components and data integrity. However, it's not a standalone diagnostic performance study (e.g., sensitivity/specificity for a given condition), as the device "does not make any diagnostic conclusion about the subject's condition." Its essential performance is to record and transfer EEG data.

7. Type of Ground Truth Used

• For Clinical Performance (Pediatric Extension): Expert consensus/review. The "experienced pediatric epileptologist" reviewed the REMI EEG data to assess its quality and presence of EEG features.
• For Technical Performance (Software, Electrical, etc.): Predetermined engineering specifications, compliance with recognized standards, and functional verification.

8. Sample Size for the Training Set

• The document does not mention a training set or machine learning model being the primary focus of this submission. The device is described as a "physiological signal monitor" that "does not make any diagnostic conclusion." The clinical experience discussed references "318 pediatric patients with a mean REMI Sensor wear of 1.7 days" from NIH-funded studies initially used for "REMI development efforts," which could have implicitly involved some level of data-driven development or refinement, but it's not explicitly framed as a "training set" for a distinct AI algorithm evaluated in this 510(k). The focus of this 510(k) is the extension of the device's indications to a younger pediatric age group and the new hydrocolloid sticker.

9. How the Ground Truth for the Training Set Was Established

• As a training set is not explicitly referred to as part of a machine learning model specific to this 510(k)'s purpose, the method for establishing its ground truth is not detailed. The "REMI development efforts" data (n=318) was collected "under Institutional Review Board oversight." However, for the specific aspect of this 510(k) (pediatric extension), the ground truth for the test set (n=13) was established via retrospective review by an experienced pediatric epileptologist.

Ask a specific question about this device

The IceCaps (IceCap 2, IceCap 2 Small, IceCap Neonate (Sizes XS, S, & M)) are medical devices used as EEG electrodes. They are used by Healthcare Professionals on a patient in case of neurological disorders with a short or long-term EEG record (up to 72 hours).
IceCap 2 shall be placed on patients weighing at least 10 kg (22.05 lbs) and having a head circumference above 43 cm (16.93 inches).
IceCap Neonate shall be placed on the head of babies, newborns and premature babies.

The IceCaps (IceCap 2, IceCap 2 Small, IceCap Neonate (Sizes XS, S, & M)) are medical devices used as EEG electrodes.
The IceCaps are a single use cap which connects to the marketed EEG recorders using an IceAdapter or Touchproof adapter.
The electrodes placement in IceCap Product line is done accordingly to the 10/20 system.
The conductive tracks of the Flexible Printed Circuit are used to conduct EEG signals from the electrodes to the connectors.
IceCap 2 shall be placed on patients weighing at least 10 kg (22.05 lbs) and having a head circumference above 43 cm (16.93 inches).
IceCap Neonate (M,S,XS) shall be placed on the head of babies, newborns and premature babies.

The IceCap product line does not perform comparative effectiveness studies with human readers or standalone algorithm performance studies. The device is a cutaneous electrode, and its evaluation focuses on safety and performance according to relevant standards, not on AI-driven diagnostic accuracy.

Here's a breakdown of the acceptance criteria and supporting studies for the IceCap product line:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

The provided document does not explicitly state the sample size used for specific test sets (e.g., for fit-to-form, impedance, or usability tests). It mentions that the "clinical data were not necessary to determine substantial equivalence," indicating that animal or human subject testing for diagnostic or comparative effectiveness was not performed as a primary means of establishing substantial equivalence for this type of device.

The document does not provide information on the country of origin of the data or whether the data was retrospective or prospective. The studies primarily involve non-clinical performance and safety testing.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

As this device is an EEG electrode, the primary "ground truth" for its performance is its ability to meet electrical and biocompatibility standards, and to effectively acquire EEG signals as confirmed by non-clinical tests. There is no mention of human experts being used to establish a ground truth for a diagnostic outcome, as the device itself does not provide diagnostic interpretations.

4. Adjudication Method for the Test Set

Not applicable. The evaluation performed is based on compliance with harmonized standards and engineering tests, not on human-based adjudication of diagnostic outcomes.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. The IceCap product line is an EEG electrode, not an AI-powered diagnostic tool. Therefore, MRMC studies with human readers are not relevant to its clearance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

Not applicable. The device is a hardware component (EEG electrode) and does not involve a standalone algorithm for performance evaluation in a diagnostic context.

7. The type of ground truth used

The ground truth used for evaluating the IceCap product line is based on established engineering standards and regulatory requirements for medical devices, particularly for cutaneous electrodes. This includes:

• Performance standards: e.g., electrical impedance, signal integrity (implied by "general quality of signal").
• Safety standards: e.g., electrical safety (IEC 60601-1), electromagnetic compatibility (IEC 60601-1-2), usability for medical electrical equipment in the home healthcare environment (IEC 60601-1-11).
• Biocompatibility standards: (ISO 10993-1) for materials in contact with the patient.
• Functional tests: Fit-to-form, usability for installation.
  The "truth" is whether the device meets these specified, measurable criteria.

8. The Sample Size for the Training Set

Not applicable. This device is a hardware product (EEG electrode) and does not involve AI or machine learning algorithms that require a training set.

9. How the Ground Truth for the Training Set Was Established

Not applicable. This device is a hardware product (EEG electrode) and does not involve AI or machine learning algorithms that require a training set or ground truth for training.

Ask a specific question about this device

Delphi MCS Electrode Cap is an EEG electrode set intended for routine clinical settings where rapid placement of large number of EEG electrodes is desired.

The Delphi MCS Electrode Cap is made of elastic textile material, preserving the shape and size. The cap provides the exact position of the electrodes on the head without the need for additional measurements and adjustments. Large holes are provided for ventilation and access to the electrodes and patient's skin. The cap is fixed to the head with a chinstrap. The Cap is available in the following sizes: XL 60-66cm, XL/L 57-63cm, L 54-60cm, L/M 51-57cm, M 48-54cm. The textile caps sizes are identifiable by the color material or seam and marking according to international system 10-20.

The Ag/AgCl electrodes are designed to provide minimal polarization and long-term stability of the signal. The conductive surface of the electrodes which is housed inside the electrode base does not have direct skin contact; an electrically conductive substance (hydrogel) is used inside the electrode base for improved conductivity.

Delphi Cap electrodes are thin cup Ag/AgCl sintered electrode for EEG recording. The electrodes are designed for maximum comfort while the patient in a supine position. The design of this electrode is suitable for conducting combined TMS-EEG studies. The Ag/AgCl sintered electrode material guarantees minimum polarization and long-term signal stability, as well as an increased electrode life.

The provided text does not contain information about acceptance criteria for a device's performance, nor does it detail a study that proves a device meets such criteria in terms of clinical effectiveness or diagnostic accuracy. Instead, the document describes the substantial equivalence claim for a new medical device, the "Delphi MCS Electrode Cap," in comparison to a predicate device, the "Electro-Cap System."

The document primarily focuses on demonstrating that the new device shares the same intended use and similar technological characteristics as the predicate device, and that any differences do not raise new safety or effectiveness concerns.

Here's a breakdown of what is provided, and what is missing based on your request:

Information Present (related to device evaluation):

• Device Name: Delphi MCS Electrode Cap
• Intended Use: "Delphi MCS Electrode Cap is an EEG electrode set intended for routine clinical settings where rapid placement of large number of EEG electrodes is desired."
• Performance Data (Non-Clinical Bench Tests):
  • Biocompatibility: Cytotoxicity, Sensitization, Irritation (per ISO 10993 standards)
  • Electrical safety (per IEC 60601-1)
  • Use cycle reliability and durability testing (resistance, noise, impedance, durability, repeated cleaning cycles)
  • AC Impedance
  • Offset Voltage
  • Combined offset instability and internal noise
  • Bias current tolerance
  • Shelf Life
  • Conductive connection compliance
• Conclusion of Performance Tests: "The results of the performance bench testing support the safety profile of the device and demonstrate that the device functions as intended." (This indicates the device met some internal performance objectives for these bench tests, but specific acceptance criteria and detailed quantitative results are not provided.)

Missing Information (as per your request):

1. A table of acceptance criteria and the reported device performance: While non-clinical tests are listed, the specific acceptance criteria for each test (e.g., maximum allowed impedance, specific thresholds for cytotoxicity) and the quantitative reported performance of the Delphi MCS Electrode Cap against these criteria are not provided in this document. The document only states that the tests were "successful" and "support the safety profile" and "demonstrate that the device functions as intended."
2. Sample sized used for the test set and the data provenance: Not applicable to the type of non-clinical bench testing reported.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable, as this is bench testing, not a clinical study requiring expert ground truth for interpretation.
4. Adjudication method: Not applicable.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done: No, not mentioned. This type of study would be relevant for devices that involve human interpretation of output (e.g., AI for image diagnosis), which is not the primary function of an EEG electrode cap.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable, as this device is an electrode cap, not an algorithm.
7. The type of ground truth used: Not explicitly stated for each bench test, but implied to be based on established standards and physical/electrical measurements.
8. The sample size for the training set: Not applicable, as this is a physical medical device, not an AI/ML algorithm requiring a training set.
9. How the ground truth for the training set was established: Not applicable.

In summary, the provided FDA 510(k) clearance letter and summary primarily address the safety and technical similarity of the Delphi MCS Electrode Cap to a predicate device through non-clinical bench testing. It does not detail specific acceptance criteria for clinical performance or diagnostic accuracy, nor does it describe a clinical study comparing its effectiveness or AI-assisted performance against human readers.

Ask a specific question about this device